01 Growing Use of High-Functionality Excipients in Advanced Tablet Manufacturing The sugar-based excipients market is shifting toward highly functional grades designed for direct compression, continuous manufacturing, and patient-friendly dosage forms. Pharmaceutical producers increasingly need lactose, mannitol, sorbitol, sucrose, and related materials that provide several functions, including filling, binding, taste improvement, stability, and powder flow. Better control of particle size, moisture, and compressibility helps manufacturers produce tablets faster while maintaining dose uniformity. Demand is also moving toward grades suitable for orally disintegrating tablets, chewables, powders, and sensitive active ingredients. This transition is making consistent performance, detailed material data, and compatibility with automated manufacturing more important competitive factors than basic sweetness or bulk alone. May 2025: A peer-reviewed pharmaceutical study highlighted the expanding use of mannitol in direct-compression tablets, including its growing role as an alternative to lactose in solid drug formulations.
01 Expansion of Generic Drug Production Increases Excipient Demand Expanding production of generic medicines and solid oral drugs is increasing demand for sugar-based excipients. Tablets and capsules require reliable fillers, binders, coatings, and sweetening agents to achieve the correct size, strength, taste, and drug-release behaviour. Lactose and mannitol are widely suited to high-volume manufacturing because their physical properties can support granulation or direct compression. Each newly approved formulation may require a specific excipient grade and validated supplier, creating recurring demand throughout commercial production. Government efforts to improve access to affordable medicines are also supporting generic manufacturing. As production volumes increase, pharmaceutical companies need dependable supplies of compendial-grade excipients with consistent quality across batches and manufacturing locations.
01 Strict Quality Requirements Increase Qualification Costs Strict quality requirements and costly supplier qualification can limit participation in the sugar-based excipients market. Materials used in medicines must meet tighter purity, microbial, traceability, and consistency standards than food-grade sugars. Manufacturers must control raw materials, validate processes, investigate changes, and provide detailed documentation to pharmaceutical customers. Drug producers may also need audits, incoming testing, and compatibility studies before approving a new excipient source. These requirements protect patients but lengthen sales cycles and raise operating costs, especially for smaller suppliers. Once a formulation is approved, changing the excipient grade or producer can require additional studies and regulatory filings, making customers reluctant to adopt alternative sources.
01 Patient-Friendly and Complex Drug Formulations Create New Applications Patient-friendly medicines create opportunities for sugar alcohols and speciality carbohydrate excipients. Children, older adults, and patients with swallowing difficulties often benefit from chewable, dispersible, liquid, or orally disintegrating products. Mannitol and sorbitol can improve taste and mouthfeel, while lactose and other carbohydrates can provide bulk, flow, and tablet strength. Sucrose, trehalose, and mannitol can also help stabilise selected proteins or freeze-dried products, expanding applications beyond conventional tablets. Custom particle engineering and technical assistance can further reduce development time for complex or personalised dosage forms.
01 Excipient Contamination Creates Serious Patient-Safety Risks Preventing contamination and maintaining consistent pharmaceutical quality across global supply chains remains a major challenge. Sugar-based liquids and polyols such as sorbitol can be vulnerable to substitution or contamination with toxic industrial chemicals if suppliers, distributors, or incoming materials are not properly controlled. Manufacturers therefore need qualified sources, identity testing, impurity controls, and secure traceability from production to delivery. These safeguards increase cost and testing time, but weak controls can cause medicine recalls, regulatory action, severe patient harm, and loss of confidence in the excipient supply chain.
June 2026 Roquette showcased its expanded portfolio of pharmaceutical excipients and advanced drug delivery solutions at CPHI China 2026 under the “One Roquette for Innovations” initiative, highlighting new formulation technologies for next-generation oral and specialty pharmaceutical products.
April 2026 Roquette expanded its consumer healthcare portfolio at Vitafoods Europe 2026, presenting enhanced excipient solutions designed for nutraceutical and pharmaceutical formulations, strengthening its position in functional oral dosage technologies.
May 2025 Roquette completed the acquisition of IFF Pharma Solutions, significantly expanding its pharmaceutical excipient portfolio, global manufacturing footprint, and formulation capabilities to strengthen its leadership in drug delivery and oral dosage solutions.
May 2025 Colorcon entered an exclusive multi-year partnership with ASHA Cellulose to commercialize ASHACEL® ethyl cellulose excipients across Europe, the Middle East, Africa, Northeast Asia, and Southeast Asia, expanding its specialty excipient offerings for controlled-release and taste-masking pharmaceutical formulations.